GIVLAARI (GIVOSIRAN SODIUM)
GIVLAARI (GIVOSIRAN SODIUM) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: GIVLAARI; Generic name: GIVOSIRAN SODIUM; Manufacturer: Alnylam Pharmaceuticals, Inc..
| Brand name | GIVLAARI |
|---|---|
| Generic name | GIVOSIRAN SODIUM |
| Manufacturer | Alnylam Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP). ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dose of GIVLAARI is 2.5 mg/kg once monthly by subcutaneous injection. ( 2.1 ) 2.1 Recommended Dosage The recommended dose of GIVLAARI is 2.5 mg/kg administered via subcutaneous injection once monthly. Dosing is based on actual body weight. Missed Dose Administer GIVLAARI as soon as possible after a missed dose. Resume dosing at monthly intervals following administration of the missed dose. Dose Modification for Adverse Reactions In patients with severe |
| Active ingredient(s) | GIVOSIRAN SODIUM |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167e663c-11e1-497b-a3fc-951d65d58eaa |